CN104662423A - 阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ - Google Patents

阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ Download PDF

Info

Publication number
CN104662423A
CN104662423A CN201380021783.5A CN201380021783A CN104662423A CN 104662423 A CN104662423 A CN 104662423A CN 201380021783 A CN201380021783 A CN 201380021783A CN 104662423 A CN104662423 A CN 104662423A
Authority
CN
China
Prior art keywords
experimenter
amount
disease
monomer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380021783.5A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·基德
约翰尼斯·鲁尔夫·施特雷费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Alzheimer Immunotherapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Alzheimer Immunotherapy filed Critical Janssen Alzheimer Immunotherapy
Publication of CN104662423A publication Critical patent/CN104662423A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380021783.5A 2012-03-13 2013-03-13 阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ Pending CN104662423A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610390P 2012-03-13 2012-03-13
US61/610,390 2012-03-13
PCT/US2013/031018 WO2013138512A1 (en) 2012-03-13 2013-03-13 OLIGOMERIC Aβ IN THE DIAGNOSIS, PROGNOSIS, AND MONITORING OF ALZHEIMER'S DISEASE

Publications (1)

Publication Number Publication Date
CN104662423A true CN104662423A (zh) 2015-05-27

Family

ID=49161786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380021783.5A Pending CN104662423A (zh) 2012-03-13 2013-03-13 阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ

Country Status (7)

Country Link
US (1) US20130273574A1 (enExample)
EP (1) EP2825884A4 (enExample)
JP (1) JP2015511014A (enExample)
CN (1) CN104662423A (enExample)
CA (1) CA2867338A1 (enExample)
HK (1) HK1206423A1 (enExample)
WO (1) WO2013138512A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105542005A (zh) * 2016-02-03 2016-05-04 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
CN108348776A (zh) * 2015-06-30 2018-07-31 健康研究公司 基于测定蛋白水解通路对阿尔茨海默病进行的诊断检验
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
CN111393524A (zh) * 2020-02-20 2020-07-10 北京化工大学 基于金属标记的阿尔兹海默症脑组织Aβ蛋白的原位检测方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140128230A (ko) 2013-04-26 2014-11-05 한국과학기술연구원 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트
JP6883847B2 (ja) * 2017-03-30 2021-06-09 国立大学法人滋賀医科大学 アミロイドβ蛋白並びにタウ蛋白及び／又はリン酸化タウ蛋白の測定方法
AU2018392605B2 (en) 2017-12-19 2025-06-12 Chase Therapeutics Corporation Methods for developing pharmaceuticals for treating neurodegenerative conditions
WO2019167830A1 (ja) * 2018-02-27 2019-09-06 株式会社 島津製作所 ＡＰＰ６６９－ｘのＮ末端を特異的に認識する抗体、及び免疫測定法
KR101977410B1 (ko) * 2018-08-22 2019-05-10 주식회사 피플바이오 당뇨병에 대한 신규 바이오마커 및 그의 용도
WO2020179224A1 (ja) * 2019-03-01 2020-09-10 株式会社島津製作所 Ａｐｐ６６９－７１１の測定方法、及び測定用キット
WO2020198866A1 (en) * 2019-04-04 2020-10-08 The Royal Institution For The Advancement Of Learning / Mcgill University USE OF Aß34 TO ASSESS ALZHEIMER'S DISEASE PROGRESSION
CN114174830A (zh) * 2019-07-10 2022-03-11 托多斯医疗有限公司 使用来自临床诊断的阿尔茨海默病受试者的血液样本的阿尔茨海默病的生物标志物
CN114555631A (zh) * 2019-08-13 2022-05-27 华盛顿大学 检测MTBR tau同种型的方法及其用途
WO2021090910A1 (ja) * 2019-11-08 2021-05-14 セントラル硝子株式会社 タンパク質凝集塊を検出する分子構造変質剤、その検出方法、医療器具用洗浄剤、土壌洗浄剤及び土壌の洗浄方法
WO2022150754A2 (en) * 2021-01-11 2022-07-14 University Of Florida Research Foundation, Incorporated Anticancer compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768076A (zh) * 2003-01-31 2006-05-03 阿伯特有限及两合公司 淀粉样β(1－42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
CN101365717A (zh) * 2005-03-05 2009-02-11 艾博特股份有限两合公司 筛选方法、纯化非扩散A-β寡聚体的方法、抗所述非扩散A-β寡聚体的选择性抗体以及制备所述抗体的方法
CN101531717A (zh) * 2009-04-22 2009-09-16 北京交通大学 抗阿尔茨海默病单克隆抗体及其应用
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939075B2 (en) * 2007-01-11 2011-05-10 Philipps-Universitaet Marburg Human monoclonal anti-amyloid-beta antibodies
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
WO2009099176A1 (ja) * 2008-02-08 2009-08-13 Immunas Pharma, Inc. Aβオリゴマーに特異的に結合する抗体およびその利用
JP5747444B2 (ja) * 2010-04-27 2015-07-15 パナソニックヘルスケア株式会社 βアミロイドに関連する病的状態の診断補助方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768076A (zh) * 2003-01-31 2006-05-03 阿伯特有限及两合公司 淀粉样β(1－42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
CN101365717A (zh) * 2005-03-05 2009-02-11 艾博特股份有限两合公司 筛选方法、纯化非扩散A-β寡聚体的方法、抗所述非扩散A-β寡聚体的选择性抗体以及制备所述抗体的方法
CN101531717A (zh) * 2009-04-22 2009-09-16 北京交通大学 抗阿尔茨海默病单克隆抗体及其应用
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348776A (zh) * 2015-06-30 2018-07-31 健康研究公司 基于测定蛋白水解通路对阿尔茨海默病进行的诊断检验
CN105542005A (zh) * 2016-02-03 2016-05-04 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
CN111393524A (zh) * 2020-02-20 2020-07-10 北京化工大学 基于金属标记的阿尔兹海默症脑组织Aβ蛋白的原位检测方法
CN111393524B (zh) * 2020-02-20 2022-04-08 北京化工大学 基于金属标记的阿尔兹海默症脑组织Aβ蛋白的原位检测方法

Also Published As

Publication number Publication date
CA2867338A1 (en) 2013-09-19
HK1206423A1 (en) 2016-01-08
JP2015511014A (ja) 2015-04-13
US20130273574A1 (en) 2013-10-17
EP2825884A1 (en) 2015-01-21
EP2825884A4 (en) 2015-11-11
WO2013138512A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
CN104662423A (zh) 阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ
Meyer et al. Plasma p‐tau231, p‐tau181, PET biomarkers, and cognitive change in older adults
Sánchez-Juan et al. Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
Majbour et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
US20190185553A1 (en) Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid
Wang-Dietrich et al. The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease
US12313637B2 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43
Teunissen et al. Brain‐specific fatty acid‐binding protein is elevated in serum of patients with dementia‐related diseases
JP2019053063A (ja) 脳内のアミロイドβペプチド蓄積状態を評価するサロゲート・バイオマーカー及びその分析方法
JP2015514206A (ja) 抗ベータアミロイド抗体の検出に関する方法及びキット
MXPA03009744A (es) Proceso para el diagnostico diferencial de demencia de alzheimer, y dispositivo para este.
US20250012815A1 (en) Methods for detecting an individual as being at risk of developing a neurodegenerative disease
CN111902721B (zh) 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用
US20110082187A1 (en) Markers and methods relating to the assessment of alzheimer's disease
JP2021508370A (ja) 神経変性状態を処置するための医薬を開発するための方法
JP2022530651A (ja) アルファ－シヌクレインアッセイ
US20180134775A1 (en) Alpha-Synuclein Antibodies (7A11)
Theofilas et al. Caspase‐6‐cleaved tau is relevant in Alzheimer's disease and marginal in four‐repeat tauopathies: diagnostic and therapeutic implications
Keene et al. Luminex-based quantification of Alzheimer's disease neuropathologic change in formalin-fixed post-mortem human brain tissue
Islam et al. Novel ultrasensitive immunoassay for the selective quantification of tau oligomers and related soluble aggregates
US20220260593A1 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
US20190376984A1 (en) Methods for quantifying soluble amyloid beta and amyloid beta oligomers
Chaudhary et al. Dissecting the structural organization of multiprotein amyloid aggregates using a bottom-up approach
JP2005539228A (ja) 軽度の認知障害を示すアルツハイマー患者特有の診断方法
US20250306037A1 (en) Methods to detect ab proteoforms and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150527